SAN DIEGO, Nov. 7, 2016 /PRNewswire/ -- NI Research has released the November/December issue of NeuroPerspective, which
Photo - http://photos.prnewswire.com/prnh/20161104/436454LOGO
As NeuroPerspective publisher Harry Tracy PhD notes:
Multiple Sclerosis represents the area where neuroscience has achieved the greatest progress towards slowing the course of a CNS disease, and where patients and their physicians can choose from a variety of treatment approaches (i.e. the ABC drugs, Tysabri, the oral immunomodulators) for the treatment of RRMS. Yet all of these drugs have their own flaws and risks, and there have been no real options for Progressive MS. Both Roche and Novartis have now reported positive Phase III results in Progressive MS, for ocrelizumab and sipinimod respectively. MS is also the area where regenerative therapies are likely to emerge as an avenue to repairing the damage done, and while the first trial of Biogen's anti-lingo program failed, there are glimmers of hope from retrospective dosing analysis that this may yet be fruitful. This review covers programs from Biogen, Roche, Novartis, Teva, Sanofi, Acorda, MedDay, Merck Serono, Actelion and many more.
Pain (nociceptive/inflammatory; neuropathic pain is reviewed separately by NIR) is a ubiquitous affliction for humankind, one where some of the most effective current treatment options, the opioids, are also among the riskiest of therapeutic agents, imbued as they are with the danger of addiction, which has translated into a well-publicized epidemic. Besides the continuing search for analgesic alternatives that might approach opioid efficacy, there has been a parallel effort to develop opioids that are formulated to reduce the risk of abuse and dependency. The Pain review covers programs from Teva Pharma, Purdue Pharma, Egalet, Cara Therapeutics, Depomed, Trevena, Epiodyne, Quartet Medicine, Centrexion, Wex Pharma, and many others.
This 64 page issue also includes:
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.
A one-year (1-5 user) subscription to NeuroPerspective is $2525. Special startup and academic pricing is available. The MS/Pain review issue of NeuroPerspective is being made available as a single-issue purchase for $500.
NI Research has also published the 2016-17 edition of NeuroLicensing, which comprehensively reviews current licensing trends in the CNS area, and assesses large and midsize pharma companies in terms of their licensing agendas and performance.
NI Research's Second Opinion provides consulting services to the pharma industry on strategic direction and licensing.
Further information and online purchasing with immediate download are available at http://www.niresearch.com/onlinestore.html.
ContactHarry Tracy[email protected]760-753-6376
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ms-and-pain-reviewed-by-neuroperspective-300358012.html
SOURCE NI Research
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All